Perennial Allergic Rhinitis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 68 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Perennial Allergic Rhinitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Perennial Allergic Rhinitis - Pipeline Review, H2 2014', provides an overview of the Perennial Allergic Rhinitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Perennial Allergic Rhinitis Overview 7
Therapeutics Development 8
Pipeline Products for Perennial Allergic Rhinitis - Overview 8
Pipeline Products for Perennial Allergic Rhinitis - Comparative Analysis 9
Perennial Allergic Rhinitis - Therapeutics under Development by Companies 10
Perennial Allergic Rhinitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Perennial Allergic Rhinitis - Products under Development by Companies 14
Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development 15
Shionogi & Co., Ltd. 15
GlaxoSmithKline plc 16
Merck & Co., Inc. 17
Pfizer Inc. 18
Teva Pharmaceutical Industries Limited 19
FAES Farma SA 20
GenMont Biotech Inc. 21
VentiRx Pharmaceuticals, Inc. 22
Adamis Pharmaceuticals Corporation 23
Hanmi Pharmaceuticals, Co. Ltd. 24
Perennial Allergic Rhinitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
bilastine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
desloratadine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
fluticasone furoate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
S-555739 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
beclomethasone dipropionate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GMNL-32 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(montelukast sodium + levocetirizine dihydrochloride) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
APC-3000 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
VTX-1463 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PF-06444753 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PF-06444752 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Perennial Allergic Rhinitis - Recent Pipeline Updates 50
Perennial Allergic Rhinitis - Dormant Projects 53
Perennial Allergic Rhinitis - Discontinued Products 54
Perennial Allergic Rhinitis - Product Development Milestones 55
Featured News & Press Releases 55
May 18, 2014: QVAR real-world study to be presented at annual ATS International Conference 55
May 13, 2014: Teva Announces FDA Acceptance of sNDA Filing for Pediatric Indication for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol 55
Feb 25, 2013: Sunovion Pharma Presents New Analyses That Continue To Support Zetonna Nasal Aerosol's Efficacy In SAR And PAR At AAAAI Annual Meeting 56
Feb 22, 2013: Teva Pharma To Present Additional Data On Qnasl At 2013 AAAAI Annual Meeting 57
Nov 12, 2012: Sunovion Presents New Clinical Safety Data From Pediatric Development Program For Zetonna Nasal Aerosol At ACAAI Annual Meeting 59
Nov 09, 2012: Teva Pharma's Qnasl Demonstrates Efficacy Profile In Pediatric Patients With Seasonal Allergic Rhinitis In Phase III Study 61
Jul 30, 2012: Sunovion Pharma Announces Nationwide Availability Of ZETONNA Nasal Aerosol For Allergic Rhinitis 62
May 07, 2012: Sunovion Announces Upcoming Availability Of ZETONNA Nasal Aerosol For Allergic Rhinitis 63
Mar 26, 2012: Teva Announces FDA Approval Of QNASL For Treatment Of Allergic Rhinitis 64
Mar 05, 2012: Teva Reports Positive Results From Four Phase III Clinical Studies Of QNASL To Treat Allergic Rhinitis 64
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Tables
Number of Products under Development for Perennial Allergic Rhinitis, H2 2014 8
Number of Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Perennial Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2014 15
Perennial Allergic Rhinitis - Pipeline by GlaxoSmithKline plc, H2 2014 16
Perennial Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2014 17
Perennial Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2014 18
Perennial Allergic Rhinitis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 19
Perennial Allergic Rhinitis - Pipeline by FAES Farma SA, H2 2014 20
Perennial Allergic Rhinitis - Pipeline by GenMont Biotech Inc., H2 2014 21
Perennial Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 22
Perennial Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 23
Perennial Allergic Rhinitis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Assessment by Combination Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Perennial Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H2 2014 50
Perennial Allergic Rhinitis - Dormant Projects, H2 2014 53
Perennial Allergic Rhinitis - Discontinued Products, H2 2014 54